Skip to content


  • Poster presentation
  • Open Access

Insulin-like Growth Factor 1 (IGF-1) measurements recorded in the OZGROW database and their relation to growth response in children currently being treated with growth hormone

  • 1,
  • 2 and
  • 2
International Journal of Pediatric Endocrinology20152015 (Suppl 1) :P38

  • Published:


  • Growth Rate
  • Internal Medicine
  • Growth Hormone
  • Detailed Analysis
  • Significant Variation


IGF-1 is produced in a GH dependent fashion and measurement of IGF-1 has become increasingly common for both diagnosis of GH deficiency and to guide GH therapy. The OZGROW database records the results of IGF-1 tests performed on patients receiving GH or being assessed for GH treatment. The OZGROW database was used to determine the extent to which IGF-1 testing is performed in this population and to assess the relationship between IGF-1 levels and growth rate.


Records were obtained for children entering the OZGROW database since 2009 and who were currently receiving GH. Number of patients, visits, and frequency of IGF-1 tests was determined. The nature of IGF-1 tests, such as the units used and whether a reference range was provided was noted. Patients with at least one IGF-1 test result were selected for further analysis. IGF-1 results were standardized (where a reference range was available) by expressing them as a % of the reference range. x% = ((x -L)/(U - L)), where x is the test result and U and L are the upper and lower values of the reference range. Growth was measured as either growth velocity (GV, cm/year) or height SDS/Year over either a 6month (+/- 10 weeks but adjusted to 6m) or 1 year (+/-13weeks adjusted to 1y). Regressions (coefficient=b) and correlations (r) were performed.


829 patients were assessed representing 7573 clinic visits. 577 (69%) did not have any IGF-1 tests recorded. 25% had one test recorded, 4% had two tests, and 1% had three tests. Another 21 IGF-1 tests were noted but not used in analyses as no reference range was given. Units used were nmol/L, mmol/L, U/ml, ug/L, mg/l, and “other”. 11 results had a reference range but no units. Overall a moderate but significant relationship was found between IGF-1% and growth: 6month GV- b=0.014cm/y/%IGF-1, r=0.16, P=0.01; 6month SDS/y- b=0.005dSDS/y/%IGF-1, r=0.31, P<0.001. 1Y GV- b=0.010, r=0.14, P=0.03; 1Y SDS/y- b=0.003, r=0.31, P<0.001. More detailed analyses stratified by indication and gender will be presented.

Discussion and conclusions

IGF-1 has been recommended to titrate GH dose. We found significant variation between IGF-1% and growth response although the correlation was significant. There was also great variation in measurement units used and references ranges stated. Further analyses will focus on the relationship between GH dose and IGF-1% to help fully elucidate the value of IGF-1 testing in GH treatment.

Authors’ Affiliations

Mater Research Institute, The University of Queensland, South Brisbane, QLD, Australia
Mater Children's Hospital, South Brisbane, QLD, Australia


© Hughes et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.